Bioactivity:

BMS-986165 inhibits IL-12/23 and type I IFN pathways[1][2]. BMS-986165 is a highly selective, orally bioavailable allosteric TYK2 inhibitor for the treatment of autoimmune diseases. Which selectively binds to TYK2 pseudokinase (JH2) domain (IC50=1.0 nM) a

CAS nr:

1609392-27-9

Purity:

98%

Molecular Weight:

425,46

SMILES:

[2H]C([2H])([2H])NC(=O)C1=NN=C(NC(=O)C2CC2)C=C1NC1=CC=CC(C2=NN(C)C=N2)=C1OC

Formula:

C20H19D3N8O3

Pathway:

Immunology/Inflammation,Stem Cells,Angiogenesis,JAK/STAT signaling,Chromatin/Epigenetic,Immunology/Inflammation,Tyrosine Kinase/Adaptors

Target:

IFNAR,JAK,JAK,JAK,JAK,Interleukin,Tyrosine Kinases